View text source at Wikipedia
![]() | |
Clinical data | |
---|---|
Trade names | Biogest, Sterolibrin, Antigest B, Agelin |
Other names | SCH-12600; 6-Chloromethylenedehydroacetoxyprogesterone; 17α-Acetoxy-6-chloro-16-methylene-6-dehydroprogesterone; 16-Methylenechlormadinone acetate; 17α-Acetoxy-6-chloro-16-methylenepregna-4,6-diene-3,20-dione |
Drug class | Progestogen; Progestin; Progestogen ester |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C24H29ClO4 |
Molar mass | 416.94 g·mol−1 |
3D model (JSmol) | |
| |
|
Chlormethenmadinone acetate (CMMA), also known as chlorsuperlutin, is a progestin medication which was developed in Czechoslovakia in the 1960s.[1] It has been used in combination with mestranol in birth control pills under the brand names Biogest, Sterolibrin, and Antigest B,[2][3] and in veterinary medicine under the brand name Agelin.[4] Analogues of CMMA include bromethenmadinone acetate (bromsuperlutin), which was assessed but was never marketed,[3][5] and melengestrol acetate (methylsuperlutin), which is used in veterinary medicine.[6]